19/10/2020

Application of the ATMP Hospital Exemption in the EU

EuropaBio and its members would like to engage the European Commission and all relevant stakeholders in a discussion on the future use of the HE in the context of the new EU Pharmaceutical Strategy and its accompanying actions.
24/09/2020

Genome editing FAQ

Genome editing is an advance in biological tools with the potential for a wide range of applications.
30/06/2020

EuropaBio observations in response to Europe’s Beating Cancer Plan

EuropaBio welcomes the European Commission’s commitment to develop a European plan to fight cancer and is supportive of its overarching approach in tackling all key stages of the disease: prevention, early diagnosis, treatment, and quality of life. Above all, we strongly advocate the employment of supportive measures for health innovation to ensure that novel cancer treatments move from the laboratory to the hospital bedside as swiftly as possible.
19/06/2020

ACCELERATE FAIR Initiative Letter of Support

We do appreciate the efforts led by the FAIR Initiative and hope to continue to partner with ACCELERATE to speed up the delivery of innovative therapies to children and adolescents.
20/05/2020

EuropaBio position on Germline Genome Editing

EuropaBio and its members strongly believe that genome editing will enable the development of many solutions to the grand challenges facing both people and planet. In medicine, genome editing offers the prospect of saving lives and tackling some of the most devastating genetic diseases.
30/04/2020

How soon can we respond to COVID-19?

The development of a vaccine or an antiviral treatment is a long and complex process. So why are we hearing that a vaccine against COVID-19 may be ready in a year from now, or even sooner?